AAAAAA

   
Results: 1-17 |
Results: 17
Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy
Authors: Zanotti, KM Rybicki, LA Kennedy, AW Belinson, JL Webster, KD Kulp, B Peterson, G Markman, M
Citation: Km. Zanotti et al., Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy, J CL ONCOL, 19(12), 2001, pp. 3126-3129
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m(2) over 3 h) employed in the treatment of gynecologic malignancies
Authors: Markman, M Kennedy, A Webster, K Kulp, B Peterson, G Belinson, J
Citation: M. Markman et al., Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m(2) over 3 h) employed in the treatment of gynecologic malignancies, J CANC RES, 127(1), 2001, pp. 55-58
Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer
Authors: Markman, M Kennedy, A Webster, K Kulp, B Peterson, G Belinson, J
Citation: M. Markman et al., Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer, CLIN CANC R, 6(11), 2000, pp. 4201-4204
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and Fallopian tube and primary carcinoma of the peritoneum
Authors: Markman, M Kennedy, A Webster, K Peterson, G Kulp, B Belinson, J
Citation: M. Markman et al., Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and Fallopian tube and primary carcinoma of the peritoneum, J CL ONCOL, 19(7), 2000, pp. 1901-1905
Paclitaxel-associated hypersensitivity reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center
Authors: Markman, M Kennedy, A Webster, K Kulp, B Peterson, G Belinson, J
Citation: M. Markman et al., Paclitaxel-associated hypersensitivity reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center, J CL ONCOL, 18(1), 2000, pp. 102-105
Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia
Authors: Markman, M Kennedy, A Webster, K Peterson, G Kulp, B Belinson, J
Citation: M. Markman et al., Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia, J CANC RES, 126(5), 2000, pp. 298-300
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer
Authors: Markman, M Kennedy, A Webster, K Kulp, B Peterson, G Belinson, J
Citation: M. Markman et al., Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer, GYNECOL ONC, 79(1), 2000, pp. 116-119
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of theperitoneum
Authors: Markman, M Kennedy, A Webster, K Peterson, G Kulp, B Belinson, J
Citation: M. Markman et al., Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of theperitoneum, GYNECOL ONC, 78(3), 2000, pp. 369-372
Weekly carboplatin as a strategy to prevent severe treatment-related emesis
Authors: Markman, M Kulp, B Peterson, G Kennedy, A
Citation: M. Markman et al., Weekly carboplatin as a strategy to prevent severe treatment-related emesis, GYNECOL ONC, 78(2), 2000, pp. 265-265
The antiemetic efficacy of oral ondansetron plus intravenous dexamethasonein patients with gynecologic malignancies receiving carboplatin-based chemotherapy
Authors: Markman, M Kennedy, A Webster, K Peterson, G Kulp, B Belinson, J
Citation: M. Markman et al., The antiemetic efficacy of oral ondansetron plus intravenous dexamethasonein patients with gynecologic malignancies receiving carboplatin-based chemotherapy, GYNECOL ONC, 78(1), 2000, pp. 43-46
Declining CA-125 in an ovarian cancer patient with progression of measurable disease: A rational hypothesis for discordant results
Authors: Markman, M Kennedy, A Webster, K Peterson, C Kulp, B Belinson, J
Citation: M. Markman et al., Declining CA-125 in an ovarian cancer patient with progression of measurable disease: A rational hypothesis for discordant results, GYNECOL ONC, 77(2), 2000, pp. 321-322
Clinical features of hypersensitivity reactions to carboplatin
Authors: Markman, M Kennedy, A Webster, K Elson, P Peterson, G Kulp, B Belinson, J
Citation: M. Markman et al., Clinical features of hypersensitivity reactions to carboplatin, J CL ONCOL, 17(4), 1999, pp. 1141-1145
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions
Authors: Markman, M Kennedy, A Webster, K Peterson, G Kulp, B Belinson, J
Citation: M. Markman et al., An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions, J CANC RES, 125(7), 1999, pp. 427-429
Gastrointestinal toxicity is not a major complication of standard dose paclitaxel therapy
Authors: Markman, M Kennedy, A Webster, K Kulp, B Peterson, G Belinson, J
Citation: M. Markman et al., Gastrointestinal toxicity is not a major complication of standard dose paclitaxel therapy, GYNECOL ONC, 74(1), 1999, pp. 152-153
Persistent chemosensitivity to platinum and or paclitaxel in metastatic endometrial cancer
Authors: Markman, M Kennedy, A Webster, K Kulp, B Peterson, G Belinson, J
Citation: M. Markman et al., Persistent chemosensitivity to platinum and or paclitaxel in metastatic endometrial cancer, GYNECOL ONC, 73(3), 1999, pp. 422-423
Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias
Authors: Markman, M Kennedy, A Webster, K Kulp, B Peterson, G Belinson, J
Citation: M. Markman et al., Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias, GYNECOL ONC, 72(1), 1999, pp. 100-101
Experience with platinum-paclitaxel chemotherapy in the initial managementof papillary serous carcinoma of the peritoneum
Authors: Kennedy, AW Markman, M Webster, KD Kulp, B Peterson, G Rybicki, LA Belinson, JL
Citation: Aw. Kennedy et al., Experience with platinum-paclitaxel chemotherapy in the initial managementof papillary serous carcinoma of the peritoneum, GYNECOL ONC, 71(2), 1998, pp. 288-290
Risultati: 1-17 |